Personalised health education against health damage of COVID-19 epidemic in the elderly Hungarian population (PROACTIVE-19): protocol of an adaptive randomised controlled clinical trial by Erőss, Bálint et al.
STUDY PROTOCOL Open Access
Personalised health education against
health damage of COVID-19 epidemic in
the elderly Hungarian population
(PROACTIVE-19): protocol of an adaptive
randomised controlled clinical trial
Bálint Erőss1,2†, Zsolt Molnár1,3†, Zsolt Szakács1,4†, Noémi Zádori1,4†, Lajos Szakó1,4†, Szilárd Váncsa1,4†,
Márk Félix Juhász1,4†, Klementina Ocskay1,4†, Nóra Vörhendi1,4†, Katalin Márta1,4†, Andrea Szentesi1,2,5†,
Andrea Párniczky1,6†, Péter J. Hegyi1,4†, Szabolcs Kiss1,4,5,7†, Mária Földi1,4,5,7†, Fanni Dembrovszky1,4†,
Anna Kanjo1,4,6†, Piroska Pázmány1,4,6†, András Varró8†, Árpád Csathó9†, Zsuzsanna Helyes4,10†, Zoltán Péterfi11†,
László Czopf12†, István Kiss13†, Antal Zemplényi14,15†, Dóra Czapári1†, Eszter Hegyi1,16†, Dalma Dobszai1†,
Emőke Miklós1†, Attila Márta1†, Dominika Tóth1†, Richard Farkas1†, Nelli Farkas1,17†, Béla Birkás9†, Erika Pintér4,10†,
Gábor Pethő4,10†, Borbála Zsigmond6†, Andrea Sárközi6†, Anikó Nagy6† and Péter Hegyi1,2,4,5*†
Abstract
Background: Early reports indicate that COVID-19 may require intensive care unit (ICU) admission in 5–26% and
overall mortality can rise to 11% of the recognised cases, particularly affecting the elderly. There is a lack of
evidence-based targeted pharmacological therapy for its prevention and treatment.
We aim to compare the effects of a World Health Organization recommendation-based education and a
personalised complex preventive lifestyle intervention package (based on the same WHO recommendation) on the
outcomes of the COVID-19.
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Methods: PROACTIVE-19 is a pragmatic, randomised controlled clinical trial with adaptive “sample size re-
estimation” design. Hungarian population over the age of 60 years without confirmed COVID-19 will be approached
to participate in a telephone health assessment and lifestyle counselling voluntarily. Volunteers will be randomised
into two groups: (A) general health education and (B) personalised health education. Participants will go through
questioning and recommendation in 5 fields: (1) mental health, (2) smoking habits, (3) physical activity, (4) dietary
habits, and (5) alcohol consumption. Both groups A and B will receive the same line of questioning to assess habits
concerning these topics. Assessment will be done weekly during the first month, every second week in the second
month, then monthly. The composite primary endpoint will include the rate of ICU admission, hospital admission
(longer than 48 h), and mortality in COVID-19-positive cases. The estimated sample size is 3788 subjects per study
arm. The planned duration of the follow-up is a minimum of 1 year.
Discussion: These interventions may boost the body’s cardiovascular and pulmonary reserve capacities, leading to
improved resistance against the damage caused by COVID-19. Consequently, lifestyle changes can reduce the
incidence of life-threatening conditions and attenuate the detrimental effects of the pandemic seriously affecting
the older population.
Trial registration: The study has been approved by the Scientific and Research Ethics Committee of the Hungarian
Medical Research Council (IV/2428- 2 /2020/EKU) and has been registered at clinicaltrials.gov (NCT04321928) on 25
March 2020.
Keywords: COVID-19, SARS-CoV-2, nCov-2019, Public health, Randomised controlled trial, Prevention
Background
World Health Organization (WHO) announced the cor-
onavirus disease 2019 (COVID-2019) outbreak pan-
demic in the morning of 12 March 2020 [1]. At the time
of writing this study protocol, there are more than 770,
000 confirmed cases with 37,000 fatalities across 178
countries, according to the Center For Systems Science
and Engineering (CSSE) at Johns Hopkins University, in-
cluding 447 cases and 15 deaths in Hungary. The ten-
dency predicts that the epidemic is far from its peak [2].
As often seen in the case of other epidemics, most
cases can be asymptomatic or develop only mild symp-
toms and remain undiagnosed. Therefore, it is difficult
to estimate the true incidence and the disease outcomes
precisely [3, 4]. However, early reports indicate that it
may require intensive care unit (ICU) admission in 5–
26%, due to acute respiratory distress syndrome (ARDS)
in 17–20%, and overall mortality can rise to 11% of the
recognised cases, mostly affecting the elderly [5–8].
These numbers are comparable to the outcomes of earl-
ier coronavirus epidemics [9, 10] and more severe than
H1N1 pandemics in 2009 [11].
Significant efforts have been invested in research and
development to re-target existing and discover new
pharmacological treatments and preventive strategies
against COVID-19 [12], as indicated by the number of
submitted protocols of the currently recruiting rando-
mised trials on ClinicalTrials.gov. Nevertheless, it must be
noted that we lack evidence-based targeted pharmaco-
logical therapy for prevention and treatment alike [13].
None of the registered studies investigates the effects of
lifestyle interventions in the prevention of poor outcomes
in the COVID-19 epidemic. Advanced age and pre-
existing comorbidities, such as cancer, cardiovascular dis-
ease, or diabetes mellitus, predispose to a more severe dis-
ease course and ICU admission [6, 14–16].
The high risk of being infected with COVID-19 as well
as the social distancing and quarantining as primary rec-
ommendations for the suppression of virus transmission
may generate a high level of anxiety and mental stress
[17, 18]. In infected patients, better mental health might
even have a positive impact on disease progression and
survival [19, 20]. Therefore, efforts for better coping with
the aversive psychological states caused by the COVID-
19 outbreak have high importance in mental health re-
silience. The role of lifestyle factors and fitness in the se-
verity of COVID-19 has remained unexplored except for
two recent studies. The history of smoking is independ-
ently associated with disease progression (OR = 14.3,
95% CI 1.6–25.0) in a Chinese cohort of 78 patients [21].
Body mass index was > 25 kg/m2 in 88% of patients who
died as compared to 19% in survivors in another Chinese
cohort of 112 patients [22]. The latter seemingly contra-
dicts the results of a very recent registry analysis of al-
most 100,000 participants where higher body mass index
(indirectly, better nutritional status) proved to be neutral
or even preventive although against non-COVID-19
upper airway infections [23]. These suggest that perso-
nalised lifestyle interventions via education or counsel-
ling could be beneficial for COVID-19 outcomes.
We did not find any complex lifestyle intervention
aiming to improve outcomes of epidemic respiratory dis-
eases by a comprehensive literature search. It is likely
driven by the difficulty of organising clinical trials with
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lifestyle interventions. Most problems arise from the fol-
lowing circumstances of epidemics; (1) Exceptionally
rapid response is required from the healthcare system.
(2) Financial and human resources are often limited and
re-routed to manage basic healthcare and public health
measures. (3) Often only days are available to set up a
trial. (4) The outcomes of the epidemics can only be
guessed since the number of influencing variates is al-
most infinite. (5) We are unable to predict the number
of affected cases within a period. (6) Efforts are invested
in finding effective pharmacological targets rather in
smaller samples. (7) Quarantine is often enforced when
lifestyle factors are hard to control, and due to the re-
striction on personal interactions, informed consent, and
data collection cannot be obtained in the usual way. (8)
The legislation is not prepared to overcome the difficul-
ties of fast track authorisation and organisation of clin-
ical trials during epidemics. Unsurprisingly, no
randomised clinical trial has been performed, to investi-
gate the effects of a multicomponent preventive lifestyle
intervention on the outcomes of COVID-19 epidemic.
Our main objective is to evaluate the effects of a per-
sonalised multicomponent lifestyle intervention aiming
to improve the outcomes of COVID-19 infection in the
population over 60 years in a randomised clinical trial.
The main hypothesis of PROACTIVE-19 is that the per-
sonalised multicomponent lifestyle intervention reduces
the rate of our composite outcome consisting of the
need for intensive therapy, hospitalisation, and mortality
in the COVID-19 population.
Methods
Design
The study protocol is structured following Spirit 2013
[24]. PROACTIVE-19 is a pragmatic, randomised con-
trolled clinical trial with adaptive “sample size re-
estimation” design. This design allows interim analyses
and necessary modifications of the sample size of the
ongoing trial to ensure adequate power [25].
Legislative amendment and ethical approval
In Hungary, Act CLIV of 1997 on Health and Decree No.
23/2002 (of 9 May 2002) of the Minister of Health on Bio-
medical research on human individuals (as amended) stip-
ulates the procedure for non-interventional investigation,
according to which (1) the leader of the investigation or
the investigator shall inform the subject both verbally and
in writing, before obtaining the consent of the subject to
participate in the clinical research, and (2) the participants’
informed consent shall be written. This Act and Decree
would not have allowed commencing the clinical trial as it
would have amounted to a criminal offence. Based on our
request sent to the Prime Minister of Hungary to amend
the Decree, the Government of Hungary issued
Government Decree No. 63/2020 of 24 March 2020, ac-
cording to which the new decree amends: (1) in addition
to Section 159 of Act CLIV of 1997 on Health, subjects
with full disposing capacities can be informed about the
non-interventional investigation qualified as clinical re-
search on coronavirus via means of telecommunications;
(2) subjects may consent to participate in the clinical re-
search through telecommunications; and (3) subjects may
withdraw their consent through telecommunications.
Ethical approval: Scientific and Research Ethics Com-
mittee of the Hungarian Medical Research Council (IV/
2428- 2 /2020/EKU).
The trial organisation, committees, and boards
The corresponding centre and designer of the
PROACTIVE-19 trial is the Centre for Translational
Medicine at the Medical School, University of Pécs,
Hungary (coordinating institution and sponsor, www.
tm-centre.org).
The Steering Committee (SC) will be led by PH (princi-
pal investigator, gastroenterologist, a specialist in internal
medicine and clinical pharmacology). SC members will be
BE (gastroenterologist, a specialist in internal medicine
and primary care), ASz (interdisciplinary unit), ZM (inten-
sive care specialist), and ZH (pharmacologist, a specialist
in clinical pharmacology). There will be independent
members as well, and the SC will include a patient
representative.
The SC will supervise the trial primarily and will make
decisions regarding all critical questions (e.g., premature
termination of the study, dropouts).
Adjudication Committee (AC): The committee will in-
clude a specialist in infectious diseases (ZP), a pharma-
cologist (AV), and a paediatrician (BZ).
The study was designed by the SC and AC and was sup-
ported by the Medical School, University of Pécs. The
sponsor had no role in the design of the trial and will have
no access to the randomisation codes or the data.
The study will have independent members, including
physicians and a safety manager (LC), to comply with
current ethical regulations.
Patient and public involvement
We will perform the assessment and minor modifica-
tions in the structure and wording of data collection and
the interventions based on the operators’ and partici-
pants’ feedback after testing the protocol on 100 poten-
tially eligible subjects. Data of these subjects will not be
recorded; only anonymous feedback will be given.
Patients were not included in the recruitment and
conduct of the study. Immediately after publications,
study results will be disseminated to the population
above 60 years of age via the electronic media when,
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depending on which study arm will better, either general
or personal lifestyle intervention will be delivered.
Our interventions do not impose a considerable finan-
cial burden on patients; therefore, such compensation
will not be required. Volunteering patients, who helped
us to test the interventions, claimed that the time and ef-
forts needed to participate in the study and follow the
recommendations (of the interventions) are entirely rea-
sonable and acceptable.
Study population
Inclusion and exclusion criteria
The inclusion criteria of our selective primary preven-
tion programme are as follows: (1) age over 60 years
(that is, high-risk individuals) and (2) informed consent
to participate. The exclusion criteria are as follows: (1)
confirmed COVID-19 (active or recovered), (2) hospital-
isation at screening for eligibility, and (3) someone was
already enrolled in the study from the same community/
household (to avoid potential crosstalk between the
study arms).
Recruitment
The population will be informed about the study and
the contact details via social media platforms, news-
paper, radio, and television advertisements.
Flow and timing
A toll-free phone number will be available for all inter-
ested in participation. By dialling this number, the partici-
pant will be informed about the trial through a pre-
recorded voice message, including the study rationale,
conditions of participation, the process of the study, and
the information on data protection. Willing participants
will be redirected to an available operator, who will ascer-
tain eligibility. Following verbal consent and randomisa-
tion, the operator will obtain key personal information of
the participants and all study-related information (Fig. 1).
The allocation will not and cannot be concealed from the
operator, but it will be concealed from everyone else (par-
ticipants, caregivers, outcome assessors).
Interventions
Participants will be randomised into two groups: (A)
general health education and (B) personalised health
education. They will go through questioning and recom-
mendations in 5 domains: (1) mental health, (2) smoking
habits, (3) physical activity, (4) dietary habits, and (5) al-
cohol consumption. Both groups will receive the same
line of questioning to assess habits concerning these do-
mains (Suppl. files 1, 2).
Group A: Questioning will be done in the order as
mentioned above, followed by a general health education
aiming towards improvement of these factors with gen-
eral recommendations (the expected mean duration is
approximately 10 min).
Fig. 1 Schedule of enrollment, interventions, and assessments according to the SPIRIT statement. The asterisk indicates that the anticipated
finishing date is the end of the pandemic or development of the vaccine, but no more than 1 year from the enrolment of the last participant
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Group B: Questioning will be done in the same struc-
tured order, but an assessment of each domain will be
followed by personalised recommendations (the ex-
pected mean duration is approximately 20 min).
After the first contact, there will be follow-up calls in
both groups, with a matching schedule: every week in
the first month, every second week in the second month,
then monthly. During these encounters, all change in all
five domains since the last call will be assessed. The
structure, script, and algorithm of the initial and follow-
up lifestyle interventions are detailed in Suppl. files 3, 4,
respectively.
The operators have received any healthcare education.
Before enrolling participants, the operators have to
complete a standard training program consisting of sem-
inars on the interventions held by medical professionals,
followed by practice of scenarios. The operators will be
trained not to give additional healthcare advice, and we
will not secure other information sources, including
electronic and printed material.
Since standard delivery of the interventions and data
collection are essential, the first three and every 50th call
of each operator will be assessed. Besides, random calls
with various scripts will be made by the study staff to
test the operators’ reactions (who are unaware of the test
session), followed by detailed assessment and feedback
to ensure quality control.
Outcomes
Based on literature data [5, 26], the primary endpoint
will be defined as the composite of any of the following
in COVID-19 cases (an accredited laboratory should ver-
ify positivity), the rate of:
1. ICU admissions
2. Hospital admissions (longer than 48 h) for the
following reasons:
 Arrhythmia (causing hemodynamic instability
and requiring continuous monitoring and/or
cardiac support, as indicated by mean arterial
pressure < 65 mmHg, and/or serum lactate > 2
mmol/L)
 ARDS (severe hypoxaemic respiratory failure
indicated by a PaO2/FiO2 < 300 mmHg according
to the Berlin definition) [27]
 Circulatory shock (the requirement of
continuous vasopressor support to maintain
mean arterial pressure ≥ 65 mmHg and/or serum
lactate ≤ 2 mmol/L)
3. Deaths
Secondary endpoints are the following:
1. The number of general practitioner visits
2. The number of emergency, hospital, and intensive
care admissions
3. The length of hospitalisation and ICU stay
4. The number of organ dysfunctions and failures
(central nervous system, cardiovascular, respiratory,
renal, liver, haematological)
5. The measurable lifestyle changes (including physical
and mental health)
6. The costs of care
The primary and secondary outcomes will be assessed
upon the conclusion of the trial, at least 1 year after the
enrolment of the last participant.
Randomisation and blinding
Computer-generated random sequence randomisation
(central) will be performed, after giving informed con-
sent. Due to the expected large sample size, we will use
simple randomisation. The allocation ratio will be 1:1.
No stratification or blocking will be applied.
In the study, participants will be blinded to the know-
ledge of the details of differences between the interven-
tions. Everyone else (outcome assessors, caregivers, and
data analysts) will be blinded regarding the allocation.
Sample size calculation, interim, and final analyses
The primary outcome is estimated to occur in 20% of
COVID-19-infected cases (≥ 60 years of age) receiving
the standard of care based on Chinese reports [5]. Due
to the lack of data, we hypothesised that our interven-
tion would result in a 50% risk reduction. Considering
one interim analysis on efficacy (with the Pocock correc-
tion), 90% power, 5% alpha (superiority design, two-
sided), a dropout rate of 20% [28, 29], and assuming 10%
incidence of COVID-19 in the target population, the es-
timated sample size is 3788 (rounded up to 3800) sub-
ject per study arm. The calculation was performed by
Stata (version 15, Philadelphia, the USA).
We plan to hold three interim analyses: the first for
sample size re-estimation at 5% of the target sample size
due to the dropout rate, the second for safety assessment
at 10% of the target sample size, and the third for effi-
cacy assessment and sample size reestimation at 50% of
the target sample size. Early stopping will be executed if
(1) safety concerns arise during the interim analysis; (2)
the statistical power reaches at least 90% and p < 0.05 at
the efficacy interim analysis (stopping for benefit); (3)
the statistical power does not reach 10%, p > 0.05, and
the event number does not reach the assumed 10% for
the whole population at the efficacy interim analysis
(that is, 380 events for the primary outcome; otherwise,
the interim analysis is postponed and repeated when the
event number reaches 380 events) (stopping for futility);
and (4) the consequences of the pandemic make further
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recruitment or follow-up impossible (stopping for
unfeasibility).
In the final analysis, the intention-to-treat analysis will
be favoured over per-protocol (or “as-treated”) analysis.
We expect a full dataset for the primary endpoint (since
the Hungarian Ministry of Interior will provide these
data). If for any reason, data will be missing for the pri-
mary outcome, we will use available case analysis. The
“last observation carried forward” strategy will be
followed to impute missing data for other outcomes
measured during the study. Missing more than one con-
secutive interventions after the initial assessment or
withdrawal of consent during follow-up results in the
dropout of the patients unless hospitalisation is required
in the meantime.
In descriptive statistics, the count and percentage will
be provided for each treatment arm for binary outcomes.
For continuous outcomes, n, mean, median, interquartile
(Q3–Q1), standard deviation, minimum, and maximum
values will be provided for each treatment arm. In a uni-
variate comparative analysis, we will calculate relative
risk with 95% confidence interval (CI) when comparing
the primary endpoint between two groups (alpha = 5%)
with a reference arm using non-repeated intervention
complemented with chi-square or Fisher’s exact test (the
same strategy will be followed for binary secondary out-
comes). For continuous variables, we will use t test as-
suming unequal variances or the Mann-Whitney test.
We will perform univariate (Kaplan-Meier and Cox-
regression) and multivariate (Cox-regression) survival
analysis for binary outcomes. An adjustment will be car-
ried out at least for age, sex, and education. Mixed effect
logistic regression will be conducted to estimate the ef-
fect of the multicomponent intervention on the out-
comes, where the subject IDs will be used as a random
subject. The model will be adjusted for changes in smok-
ing habits, alcohol consumption, physical activity, and
dietary habits (or body mass index).
All analyses will be carried out with SPSS version 26
and Stata version 15.
Study duration
The planned starting date of the study is 1 April 2020,
and the anticipated finishing date is the end of the pan-
demic or development of the vaccine, but no more than
1 year from the enrolment of the last participant.
Data management
Data handling
Confidential and anonymous data handling will be per-
formed by the Data Monitoring Committee (DMC). To
be able to trace data to an individual subject, a subject
identification code list will be used. A Personal Identifi-
cation Number (PIN) will be generated to identify the
data of the participant. This PIN will be present on all
forms and documents of each individual. Electronic case
report forms (eCRFs) will be used. The Investigator will
ensure that the data in the eCRFs are accurate,
complete, and legible. Detailed data flow will be de-
scribed in a Data Management Plan (DMP). Data from
completed eCRFs will be validated under the direction
of the Data Manager on the DMC according to a Data
Cleaning Plan (DCP). Any missing, implausible, or in-
consistent recordings in the eCRFs will be referred back
to the Investigator using a data query form (DQF). They
will be documented for each subject before clean file sta-
tus is declared. All changes to eCRFs will be recorded.
The DMC will perform an independent assessment of
trial-related documents and activities to ensure respect
for subjects’ right, safety, and well-being and to guaran-
tee the plausibility of clinical data. The similarity of
groups at baseline will also be checked.
Written informed consent had to be replaced, due to
the specific circumstances (the need to maintain social
distance during the pandemic), by verbal consent ob-
tained during the first call on recruitment. The verbal
consent to participate in such clinical research had not
been permitted by the law previously. Therefore, the bill
was amended on 24 March 2020 upon the request of
our study consortium. This amendment enabled us to
conduct this trial.
After verbal consent of the subjects, the data will be
recorded by the investigator. Clinical research data are
processed separately from participants’ data under pseu-
donyms. Data may only be accessed by persons acting
under the authority of the controller and in accordance
with the authorisation system established within the
controller’s organisational structure, only to the extent
and in the manner necessary for the performance of
tasks. Personal data are not accessible to third parties.
Safety
Due to the nature of the multicomponent moderate-
intensity lifestyle intervention, we do not expect serious
adverse events. However, minor or moderate adverse
events may develop, such as alcohol and nicotine with-
drawal, weight change exceeding the optimum, and the
need for change in regular medications (antihypertensive
or antidiabetic drugs). Participants will be advised to
consult their primary care physician if any non-lifestyle-
related health issue arises except for COVID-19-related
concerns when the call will be transferred to the
COVID-19-specific national helpline immediately. If a
participant develops a potentially serious health prob-
lem, the chairman of the Safety Monitoring Board (LC)
will be notified. After the first interim analysis for safety
at 10% of the target number, the board will revise the
charts of all visits to health facilities and assess if any
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event is related to the interventions (see, early stopping
for safety).
Discussion
Neither the worldwide climax of the COVID-19 pan-
demic can be foreseen nor the potential repeated out-
breaks [2]. Although efforts of primary prevention (i.e.
vaccine development) are promising, it is expected to
take 12–18 months from now on [30]. Better lifestyle has
its unquestionable advantages not only for infectious but
also for common chronic diseases including diabetes
mellitus, chronic heart failure or malignant tumours.
Considering the recent low numbers of reported cases
and the expected trajectory of the epidemic in Hungary,
it seems that we are still on time to seek for personalised
and easily available public health interventions applicable
for the target population.
While in the USA, “remote” consent via telecommuni-
cation may be possible, the Hungarian laws have not
allowed such initiatives until now. An outbreak imposes
new challenges to the process of ethical approval [31].
Most importantly, the instant reaction of both the re-
searchers and the ethical committees is essential, while
preserving the validity of scientific content [32].
Based on the results of the current study, such strat-
egies could be introduced in other countries. Lifestyle
counselling is expected to reduce mental distress, smok-
ing, and alcohol consumption; increase physical activity;
and favourably change the body mass (along with the
body composition). As the main results of all these, the
interventions may boost the body’s cardiovascular and
pulmonary reserve capacities, leading to improved resist-
ance against the damage caused by COVID-19. Conse-
quently, lifestyle changes can reduce the incidence of
life-threatening conditions and attenuate the detrimental
effects of the pandemic seriously affecting the older
population.
Strengths and limitations
We aim to apply lifestyle interventions considered to
be safe in a broad population of subjects exposed at
high risk of a severe course of COVID-19. The ex-
pected health benefits of the interventions consider-
ably exceed its potential harms. With this study
design, we can evaluate the effectiveness of (1) the
offer of lifestyle intervention vs (2) that of the actual
uptake of or compliance to the lifestyle intervention.
We expect that the moderate intensity of the perso-
nalised multicomponent lifestyle intervention will
maximise the effectiveness and, at the same time, pre-
vents low adherence. In addition to the expected
beneficial effects regarding the infection, other pro-
tective changes are likely regarding cardiovascular and
malignant morbidity and mortality on the long-term.
The interventions are easy to be delivered while being
affordable and implementable for the vast majority of
the population.
We expect that there will be limitations in this study
[30]. We define cross-contamination that participants on
different arms deliberately and unknowingly communi-
cate with each other, leading to the loss of the true effect
of lifestyle interventions. To minimise the risk of cross-
contamination, we decided to include only one subject
from communities with multiple potential candidate par-
ticipants. Although we can evaluate the actual uptake of
the lifestyle interventions, its validity is uncertain due to
the patient-reported nature of the data. We cannot an-
ticipate the climax of the epidemics so that the infection
rate of the target population may deviate from the as-
sumed 10%. To overcome this, we use sample size-
readjustment adaptive design, which may settle the
problem with the unpredictable dropout rate as well (al-
though this method cannot counteract chronological
changes in the dropout rate throughout the evolution of
the pandemic). All data on secondary outcomes are pro-
vided by participants and other, less reliable indirect data
sources. We anticipate that volunteers give a representa-
tive sample of the target population, but we cannot ex-
clude that our study population will be somewhat better
educated and highly motivated. Despite the thorough
training of the operators, inter-operator variability may
be present.
Additional information and plans
A follow-up study (PROACTIVE-19 PLUS) is planned to
follow up patients, in which blood samples (serum and
plasma) from every patient will be stored to analyse im-
munoglobulins later if required and to build a biobank
for a future clinical study. We also intend to publish the
study protocol.
Trial status
Trial registration: The trial has been registered at the
clinicaltrials.gov (NCT04321928).
Protocol Version: V1.31.03.2020.
Start of patient recruitment: 01 April 2020.
Anticipated finishing date: the end of the pandemic or
development of the vaccine, but no more than 1 year
from the enrolment of the last participant.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04733-0.
Additional file 1.
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